Turner Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Turner Investments’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-200	Closed	-$30K	–	20
2017 Q4	$30K	Buy	200 +40	+25%	+$5.92K	2.34%	15
2017 Q3	$24K	Buy	+160	New	+$24.1K	0.11%	84
2016 Q3	–	Sell	-250	Closed	-$22K	–	230
2016 Q2	$22K	Sell	250 -7,240	-97%	-$626K	0.01%	197
2016 Q1	$595K	Sell	7,490 -1,210	-14%	-$109K	0.16%	150
2015 Q4	$1.09M	Buy	+8,700	New	+$1.05M	0.23%	131
2015 Q2	–	Sell	-16,380	Closed	-$1.93M	–	390
2015 Q1	$1.93M	Buy	+16,380	New	+$1.96M	0.35%	95
2013 Q4	–	Sell	-127,592	Closed	-$9.67M	–	653
2013 Q3	$9.67M	Buy	+127,592	New	+$10.2M	0.16%	197

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Turner Investments's VRTX Position: Q1 2018 in Review

Turner Investments sold out of Vertex Pharmaceuticals (VRTX) in Q1 2018, closing a stake of 200 shares — an estimated $30K sold.

Turner Investments first reported a position in VRTX in Q3 2013 and held it in 7 quarters. The position peaked at $9.67M in Q3 2013. 681 funds tracked by Wall St. Rank hold VRTX as of Q1 2018.

Turner Investments reported no remaining Vertex Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Turner Investments sold 200 Vertex Pharmaceuticals shares in Q1 2018, an estimated $30K.
Turner Investments first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 7 quarters.
Turner Investments's Vertex Pharmaceuticals position peaked at $9.67M in Q3 2013.
681 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2018.

Based on Turner Investments's 13F filing for Q1 2018, filed 10 May 2018.